JP7096817B2 - 三環式複素環式誘導体及びその使用 - Google Patents

三環式複素環式誘導体及びその使用 Download PDF

Info

Publication number
JP7096817B2
JP7096817B2 JP2019523810A JP2019523810A JP7096817B2 JP 7096817 B2 JP7096817 B2 JP 7096817B2 JP 2019523810 A JP2019523810 A JP 2019523810A JP 2019523810 A JP2019523810 A JP 2019523810A JP 7096817 B2 JP7096817 B2 JP 7096817B2
Authority
JP
Japan
Prior art keywords
xanthene
methyl
oxy
alkylene
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537602A (ja
JP2019537602A5 (enExample
Inventor
ジェイムズ マーシャル アンドリュー
マリー ブキャナン クリスティーナ
ウィリアム ルカーストル ゴードン
クオ－リャン ルー
アーカート フラナガン ジャック
ボネット ミュリエル
ロビン シェパード ピーター
マイケル フレイザー ジェイミソン スティーブン
アクラティヤ ガマゲ スワルナラサ
アレクサンダー デニー ウィリアム
Original Assignee
オークランド ユニサービシーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサービシーズ リミティド filed Critical オークランド ユニサービシーズ リミティド
Publication of JP2019537602A publication Critical patent/JP2019537602A/ja
Publication of JP2019537602A5 publication Critical patent/JP2019537602A5/ja
Application granted granted Critical
Publication of JP7096817B2 publication Critical patent/JP7096817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
JP2019523810A 2016-11-04 2017-11-03 三環式複素環式誘導体及びその使用 Active JP7096817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ72576716 2016-11-04
NZ725767 2016-11-04
PCT/IB2017/056848 WO2018083635A2 (en) 2016-11-04 2017-11-03 Tricyclic heterocyclic derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2019537602A JP2019537602A (ja) 2019-12-26
JP2019537602A5 JP2019537602A5 (enExample) 2020-12-10
JP7096817B2 true JP7096817B2 (ja) 2022-07-06

Family

ID=62075593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523810A Active JP7096817B2 (ja) 2016-11-04 2017-11-03 三環式複素環式誘導体及びその使用

Country Status (6)

Country Link
US (1) US11028064B2 (enExample)
EP (1) EP3535243B1 (enExample)
JP (1) JP7096817B2 (enExample)
CN (1) CN110139852A (enExample)
AU (1) AU2017355603A1 (enExample)
WO (1) WO2018083635A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240821B1 (ko) * 2017-03-13 2021-04-15 광주과학기술원 Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 5-히드록시 피리딘계 화합물 및 이를 포함하는 약학적 조성물
CN108976164A (zh) * 2018-06-20 2018-12-11 南通常佑药业科技有限公司 手性哌啶胺化合物的制备方法及手性拆分剂的回收套用方法
WO2021101521A1 (en) * 2019-11-19 2021-05-27 Provecetus Pharmatech, Inc. Composition and method for treating hematologic cancers
BR112023004719A2 (pt) * 2020-09-21 2023-04-18 Hutchison Medipharma Ltd Compostos heteroaromáticos e usos dos mesmos
CN114890899B (zh) * 2022-04-02 2023-10-03 南京农业大学 一种制备二苯醚酯类化合物的方法
CN115557890B (zh) * 2022-09-01 2024-06-25 宁波大学 一种多取代吖啶酮烷基衍生物及其制备方法和用途
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506948A (ja) 2006-10-20 2010-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｃ−ｋｉｔおよびｐｄｇｆｒ受容体を調節するための組成物および方法
WO2013161816A1 (ja) 2012-04-23 2013-10-31 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1192651A (en) * 1968-01-09 1970-05-20 Sterling Drug Inc Xanthene Derivatives
BE759292A (fr) 1969-11-27 1971-05-24 Allen & Hanburys Ltd Derives de xanthone, leur preparation et leur emploi
US3859286A (en) * 1970-12-11 1975-01-07 Richardson Merrell Inc Bis-basic ketones of xanthene and xanthen-9-one
EP0278176B1 (en) 1986-12-23 1994-03-09 Warner-Lambert Company Compounds having antitumour and antibacterial properties
AU2002367773A1 (en) 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
WO2005003131A1 (en) 2003-06-27 2005-01-13 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators
AU2005335481A1 (en) 2004-08-05 2007-04-19 Janssen Pharmaceutica N.V. Tricyclic delta- opioid modulators
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
PE20080359A1 (es) 2006-04-19 2008-06-06 Novartis Ag Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
WO2008016661A2 (en) * 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
WO2008048117A2 (en) 2006-10-17 2008-04-24 Auckland Uniservices Limited Synthesis of 5,6-dimethyl-9-oxo-9h-xanthen-4-yl- acetic acid (dmxaa)
CN101195609B (zh) 2007-09-28 2011-04-20 武汉远大制药集团有限公司 5,6-二甲基呫吨酮-4-乙酸的制备方法及由此方法制备的衍生物和药物制剂
DE102007047495B4 (de) 2007-10-04 2009-07-16 Contitech Kühner Gmbh & Cie. Kg Wellrohrschlauchleitung sowie Verfahren zu deren Herstellung
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
CN101279967B (zh) 2008-05-29 2010-11-10 武汉远大制药集团有限公司 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
AR072295A1 (es) 2008-06-26 2010-08-18 Novartis Ag Metodo de preparacion del acio 5,6-dimetil-9-oxo-9h-xanten-4-il-acetico
US20110201678A1 (en) 2008-10-17 2011-08-18 Masse Craig E Xanthenone-4-Acetic Acid Derivatives
AU2010295622A1 (en) * 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
UA108222C2 (xx) 2009-12-21 2015-04-10 СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
TWI414520B (zh) 2010-10-06 2013-11-11 Nat Defense Medical Ct 噻噸酮衍生物
PH12013501221A1 (en) 2010-12-13 2022-03-30 Array Biopharma Inc SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
NO2694640T3 (enExample) 2011-04-15 2018-03-17
EP2791143B1 (en) 2011-12-15 2016-02-24 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
GB2498976A (en) 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506948A (ja) 2006-10-20 2010-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｃ−ｋｉｔおよびｐｄｇｆｒ受容体を調節するための組成物および方法
WO2013161816A1 (ja) 2012-04-23 2013-10-31 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors

Also Published As

Publication number Publication date
EP3535243A4 (en) 2020-05-06
JP2019537602A (ja) 2019-12-26
EP3535243B1 (en) 2021-12-15
WO2018083635A2 (en) 2018-05-11
AU2017355603A1 (en) 2019-06-20
EP3535243A2 (en) 2019-09-11
US11028064B2 (en) 2021-06-08
WO2018083635A3 (en) 2018-07-26
CN110139852A (zh) 2019-08-16
US20190276423A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
JP7096817B2 (ja) 三環式複素環式誘導体及びその使用
JP7462985B2 (ja) 芳香族化合物および抗腫瘍薬物の調製におけるその使用
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP2022081606A (ja) Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP7035055B2 (ja) Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体および疾患の処置におけるそれらの使用
JP2021515033A (ja) がんを治療するためのｈｐｋ１阻害剤としてのｎ−（フェニル）−２−（フェニル）ピリミジン−４−カルボキサミド誘導体及び関連化合物
US20060235037A1 (en) Heterocyclic inhibitors of protein arginine methyl transferases
JP2021006579A (ja) トリプトファンジオキシゲナーゼ（ｉｄｏ１とｔｄｏ）の阻害剤及び治療におけるその使用
US20180179179A1 (en) Heterocyclic compounds as immunomodulators
CN102947272A (zh) 用作atr激酶抑制剂的2-氨基吡啶衍生物
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
US10344017B2 (en) Pyrrolcarboxamide derivatives for the inhibition of ERK5
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
JP2017512783A (ja) ピペリジン−ジオン誘導体
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
AU2019339006B2 (en) 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo (4, 5-c) cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
JP2017526720A (ja) キナーゼ阻害剤としての化合物および組成物
TW202216712A (zh) 一種高活性的ｈｐｋ１激酶抑制劑
JP6446461B2 (ja) イミダゾピラジノン誘導体
AU2018321135B2 (en) Azaindolylpyridone and diazaindolylpyridone compounds
CN116134022B (zh) Atr抑制剂和其用途
EP3012259A1 (en) Five-membered heterocyclic pyridine compounds and preparation method and use thereof
AU2024240851A1 (en) Triazine compound and use thereof
WO2025026997A1 (en) Substitued bicyclic heterocyclic yap-tead and/or taz-tead inhibitors
HK40072566A (en) Azaindolylpyridone and diazaindolylpyridone compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220624

R150 Certificate of patent or registration of utility model

Ref document number: 7096817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250